A Study to Evaluate the Veniti Vici™ Venous Stent System in Patients with a Chronic Iliofemoral Venous Outflow Obstruction

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of the Veniti Vici™ Venous Stent System in relation to pre-defined objective performance goals when used to treat a chronic non-cancerous blockage of the iliofemoral vein.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria 

  • Pre-procedure criteria
    • Age ≥ 18 years
    • Willing and capable of complying with all follow-up evaluations at the specified times
    • Able and willing to provide written informed consent prior to study-specific procedures
    • Has a unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter (to be measured by venogram during procedure)
    • Has clinically significant venous obstruction defined as meeting at least one of the following clinical indicators
      • Clinical severity class of CEAP classification ≥3
      • VCSS Pain Score ≥2
    • Negative pregnancy test in females of child-bearing potential
    • Intention to stent the target lesion only with the Veniti Vici Venous Stent

Exclusion Criteria

  • Pre-procedure criteria
    • Has the presence or history of clinically significant pulmonary emboli within 6 months prior to enrollment
    • Venous obstruction that extends into the inferior vena cava
    • Contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof with planned treatment within 30 days after subject enrollment
    • Life expectancy <12 months
    • Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study
    • Has uncontrolled or active coagulopathy 
    • Has known, uncorrectable bleeding diathesis with the following definitions
      • Uncorrected INR ≥2.0 or aPTT ≥1.5 X normal local lab value
      • Platelet count <80,000
      • Uncorrected hemoglobin of ≤ 9 g/dL
    • Has an estimated glomerular filtration rate (eGFR) <30 mL/min
      • In patients with diabetes mellitus, eGFR <45 mL/min
    • Has known hypersensitivity to nickel or titanium
    • Has a contrast agent allergy that cannot be managed adequately with pre-medication
    • Will have intended concurrent thrombolysis or thrombectomy procedure 
    • Will have intended or planned (within 30 days) adjuvant procedure such as creation of temporary arteriovenous fistula, placement of IVC filter, endovenectomy or saphenous vein ablation
    • Has current or recent (within 30 days) active participation in another drug or device clinical trial
      • Participation in observational studies is acceptable
    • Is judged to be a poor candidate by the primary investigator
    • Has had any prior surgical or endovascular procedure of the target vessel 
      • Catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 3 month (90 days) prior to the VIRTUS index procedure is acceptable
  •  Intra-Procedural Criteria
    • The lesions cannot be traversed with a guide wire
    • The obstruction extends into the inferior vena cava or below the level of the lesser trochanter
    • Vein diameters are not within limits stated in current Instructions for use as determined by venogram
    • Do not meet the venogram binary stenosis definition, as determined by the treating physician

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Haraldur Bjarnason, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20258277

Mayo Clinic Footer